A team of chemists, biologists and microbiologists led by researchers in Arts & Sciences at Washington University in St.

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Blujepa is the first new type of oral antibiotic to treat UTIs to gain approval in more than 20 years. Its development was ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

First, we need to understand how drugs… Receive a weekly dose of discovery in your inbox! We'll also keep you up to date with New Scientist events and special offers. What is vibe coding ...

At a time when it is easy to be overwhelmed with pessimism, there are plenty of reasons to be optimistic about Ireland’s ...

has the promise to lead to new paradigms and cost savings in drug development, all of which would strengthen the industry and its ability to develop innovative and much-needed therapies for ...

Trump’s administration this week abruptly terminated funding for a slew of studies designed to learn how to better treat the ...

Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ETCompany ParticipantsGabby Woody - Executive Assistant, ...